# Respiree

> Respiree is a Singapore-founded digital health company (an A*STAR spin-off) building clinically validated AI that pairs FDA-cleared cardio-respiratory wearable sensors with software to track lung and heart biomarkers over time. Its 1Bio platform helps hospitals, health systems and biopharma detect patient deterioration - such as COPD flare-ups and heart failure - days in advance, powering remote patient monitoring, clinical decision support and decentralized clinical trials across Asia-Pacific, Australia and the United States.

- **Founded:** 2019
- **Headquarters:** Singapore (with US HQ at Texas Medical Center Innovation, Houston, USA)
- **Founders:** Gurpreet Singh (Founder & CEO)
- **Team size:** Approximately 40 employees (registry sources cite ~33; figure is approximate)
- **Products:** 1Bio Platform, 1Bio AI-Acute, RS001 Cardio-Respiratory Sensor, Respiree Care, Decentralized Clinical Trials Platform
- **Notable:** US FDA 510(k) clearance for the RS001 cardio-respiratory sensor (2023), CE mark (Europe) and Australia TGA approval, Singapore HSA clearance of 1Bio AI-Acute - reportedly the first AI alternative to an inpatient Early Warning Score approved in Singapore

## Products & services

- **1Bio Platform** — Flagship AI/ML platform that integrates EHR data, mobile questionnaires, third-party devices and Respiree's FDA-cleared sensors to longitudinally track disease progression across thousands of pulmonary-cardio multi-modal biomarkers. Includes the 1Bio AI-Acute toolbox.
- **1Bio AI-Acute** — Software-as-a-medical-device toolbox cleared by Singapore's HSA - reportedly the first AI-powered alternative to an inpatient Early Warning Score approved in Singapore.
- **RS001 Cardio-Respiratory Sensor** — FDA-cleared wearable chest patch measuring heart rate, respiration and temperature in real time, paired with a fingertip oximeter for SpO2.
- **Respiree Care** — Enterprise remote-care / remote patient monitoring solution for hospital-at-home, chronic disease management and rehabilitation, with EHR integration.
- **Decentralized Clinical Trials Platform** — Digital biomarker discovery and real-world data aggregation platform for biopharma, enabling remote clinical data acquisition across distributed trial sites.

## Achievements

- US FDA 510(k) clearance for the RS001 cardio-respiratory sensor (2023)
- CE mark (Europe) and Australia TGA approval
- Singapore HSA clearance of 1Bio AI-Acute - reportedly the first AI alternative to an inpatient Early Warning Score approved in Singapore
- ISO 13485 (medical device QMS) and ISO 27001:2022 certification; HIPAA and FDA cybersecurity compliance
- President's Technology Award 2024
- ATS 2022 Respiratory Innovation Summit Featured Start-up; Falling Walls Finalist 2022
- US$11.6M Series A closed in 2025 with Mayo Clinic among investors

## Latest updates

- **2026-06** — Appointed Patty Riskind - who previously scaled Qualtrics' healthcare division - as Chair of the Board of Directors.
- **2026-02** — One Six 8 Ventures, a Canadian med-tech fund, joined Respiree's Series A syndicate to support North American expansion.
- **2025-07** — Closed a US$11.6M Series A co-led by We Venture Capital and ClavystBio; established US HQ at Texas Medical Center Innovation in Houston.
- **2024-04** — Incorporated in the US and joined the JLABS @ San Francisco residency.

## Links

- Website: https://respiree.com
- LinkedIn: https://www.linkedin.com/company/respiree

---

Profile page: https://yespress.io/respiree
Published by YesPress — https://yespress.io
Last updated: 2026-07-25